佐藤宏樹

Sato Hiroki

競争的資金等の研究課題 (9件)：

全件表示

論文 (61件)：

Kanako Moritoh, Koichiro Shoji, Yosuke Amagai, Tomoko Fujiyuki, Hiroki Sato, Misako Yoneda, Chieko Kai. Immune response elicited in the tumor microenvironment upon rMV-SLAMblind cancer virotherapy. Cancer science. 2023
Hiroki Sato, Miho Hoshi, Fusako Ikeda, Tomoko Fujiyuki, Misako Yoneda, Chieko Kai. Downregulation of mitochondrial biogenesis by virus infection triggers antiviral responses by cyclic GMP-AMP synthase. PLoS pathogens. 2021. 17. 10. e1009841
Akihiro Sugai, Hiroki Sato, Misako Yoneda, Chieko Kai. PIM 3 kinase, a proto-oncogene product, regulates phosphorylation of the measles virus nucleoprotein tail domain at Ser 479 and Ser 510. Biochemical and biophysical research communications. 2020. 531. 3. 267-274
Keigo Iizuka, Koichiro Shoji, Tomoko Fujiyuki, Kanako Moritoh, Kei Tamura, Asuka Yoshida, Hiroki Sato, Misako Yoneda, Kazushi Asano, Chieko Kai. Antitumor activity of an oncolytic measles virus against canine urinary bladder transitional cell carcinoma cells. Research in Veterinary Science. 2020
Tomoko Fujiyuki, Yosuke Amagai, Koichiro Shoji, Takeshi Kuraishi, Akihiro Sugai, Mutsumi Awano, Hiroki Sato, Shosaku Hattori, Misako Yoneda, Chieko Kai. Recombinant SLAM-blind measles virus is a promising candidate for nectin-4-positive triple negative breast cancer therapy. Molecular Therapy - Oncolytics. 2020

MISC (8件)：

Chieko Kai, Tomoko Fujiyuki, Hiroki Sato, Yataro Daigo, Misako Yoneda. Applicability of a recombinant SLAM-blind measles virus to breast cancer treatment. CANCER SCIENCE. 2018. 109. 274-274
Tomoko Fujiyuki, Koichiro Shoji, Keigo Iizuka, Yu Horikirizono, Hiroki Sato, Kazushi Asano, Misako Yoneda, Chieko Kai. Potential applicable range of oncolytic virotherapy with a recombinant measles virus in dogs. CANCER SCIENCE. 2018. 109. 1037-1037
Tomoko Fujiyuki, Koichiro Shoji, Akihiro Sugai, Hideki Yamaguchi, Kazuyoshi Yanagihara, Hiroki Sato, Misako Yoneda, Chieko Kai. Oncolytic activity of a recombinant SLAM-blind measles virus against scirrhous gastric cancer cells. CANCER SCIENCE. 2018. 109. 964-964
T. Fujiyuki, Y. Amagai, K. Shoji, A. Sugai, M. Awano, H. Sato, M. Yoneda, C. Kai. An oncolytic recombinant measles virus is a candidate of a novel therapeutic agent for triple negative breast cancer. HUMAN GENE THERAPY. 2017. 28. 12. A5-A5
C. Kai, T. Fujiyuki, K. Shoji, H. Sato, M. Yoneda. Development of oncolytic measles virus, rMV-SLAMblind. HUMAN GENE THERAPY. 2017. 28. 12. A25-A25

講演・口頭発表等 (1件)：

For a veterinary clinical study of a recombinant measles virus in dog cancer patients.
(11th International Conference on Oncolytic Viruses, Oxford 2018)

※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。登録・更新については、こちらをご覧ください。

佐藤 宏樹